Clinical Trials Logo

Pleural Effusion, Malignant clinical trials

View clinical trials related to Pleural Effusion, Malignant.

Filter by:

NCT ID: NCT01262612 Terminated - Clinical trials for Malignant Pleural Effusion

Cediranib as Palliative Treatment in Patients With Symptomatic Malignant Ascites or Pleural Effusion

Start date: April 2010
Phase: Phase 2
Study type: Interventional

In some patients with cancer there are also cancer cells in the abdominal cavity or between the lung membranes. These cancer cells create too much moisture in the abdominal cavity or between the lung membranes. If there is fluid in the abdominal cavity (ascites fluid) this can bring on abdominal distension, abdominal pain, loss of appetite, fatigue, bloating and sometimes wheezing. Too much fluid between the lung membranes (we call this pleural fluid) gives breathlessness, chest pain and coughing. The use of diuretics may offer a small group of patients symptom reduction. Additionally, the fluid can be drained through a needle puncture or fluid collection (through a biopsy). But usually, the moisture quickly returns. Previous research done in this hospital with cediranib showed that with some patients with cancer who suffered from fluid in the abdominal cavity or between the lung membranes, this moisture reduces while using this drug. It also reduced the symptoms caused by this excessive moisture. The current study is conducted to see whether patients with cancer and fluid in the abdominal cavity or fluid between the lung blades benefit from using cediranib. This involves not only whether the amount moisture reduces, but also if the complains decrease. In addition, we will carefully consider the possible side effects of cediranib.

NCT ID: NCT01004510 Terminated - Clinical trials for Non Small Cell Lung Cancer

Zometa Adjuvant Treatment of Malignant Pleural Effusion Due To Non-Small Cell Lung Cancer

ZAP
Start date: November 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate whether the addition of the bisphosphonate Zometa (zoledronic acid) used along with standard regimens of chemotherapy, will help to control the need for palliative intervention of malignant pleural effusions due to non-small cell lung cancer.

NCT ID: NCT00465907 Terminated - Lung Cancer Clinical Trials

Study of Weekly Paclitaxel, Carboplatin and Irinotecan to Treat Lung Cancer

Start date: May 2003
Phase: Phase 2
Study type: Interventional

Evaluate the efficacy and toxicity of the weekly combination chemotherapy of Paclitaxel, Carboplatin and Irinotecan in Stage IIIb and IV NSCLC with malignant pleural effusion

NCT ID: NCT00402896 Terminated - Lung Cancer Clinical Trials

Malignant Pleural Effusion With ZD6474

Start date: October 2006
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn the effect of ZD6474 on the amount of time between placement of an indwelling pleural catheter and the catheter's removal in patients with malignant pleural effusion. This study will also look at the effect that ZD6474 has on tumor cells, biological characteristics of cells in the body, rate of fluid build-up around the lungs, tumor size, and thickness of blood vessels. The effect that this drug has on quality of life and shortness of breath will also be examined.

NCT ID: NCT00316134 Terminated - Pleural Effusion Clinical Trials

Multiple Biomarkers in Undiagnosed Pleural Effusion

Start date: March 2006
Phase: N/A
Study type: Observational

The purpose of this clinical trial is to evaluate the ability of various biomarkers measured in serum and/or pleural fluids to estimate the risk of finding cancer in patients with undiagnosed pleural effusions. An algorithm for prediction of the risk of finding cancer in the patient using an optimal combination of markers will be developed, and patients will be categorized as having a low, moderate, or high risk of finding cancer that might be used to more effectively triage patients.